In the news

Mitchell Salloum became the first patient to receive a WATCHMAN™ implant in Wyoming. The Boston Scientific WATCHMAN implant is placed into a patient’s heart in a one-time procedure that may reduce stroke risk for a lifetime in patients with irregular heartbeats.

Many Fortune 500 companies have long-standing, well-oiled programs that often funnel into post-grad development and leadership programs or full-time jobs. For Lauren Nakamura, her marketing internship at Boston Scientific changed the course of her career and gave her confidence and reassurance that she was joining a workplace culture that prioritized work-life integration.

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

*The EMPOWER MPS is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.

The global medical device manufacturer has maintained operational continuity throughout the pandemic, using clear processes and procedures mixed with a healthy dose of care.

Our innovative TheraSphere™ technology, which increases HCC liver cancer survival rates, may be an effective treatment for other tumors.

CIO and SVP of IT Jodi Euerle Eddy, recently named one of FiercePharma’s 2021 Fiercest Women in Life Sciences, reflects on her career and the opportunity to turn Boston Scientific’s digital transformation strategy into a competitive advantage.

Our CHAMPION AF clinical trial is studying whether the WATCHMAN FLX device can reduce the risk of stroke for more people suffering from AFib. Learn more about one patient enrolled in the trial in Sydney, Australia.

How Boston Scientific built a corporate culture of diversity and equity that encourages collaboration and innovation.

New high-resolution imaging solutions from Boston Scientific are designed to provide a clearer view of the human anatomy

In the race to secure computer chips amid a global shortage, medical device makers say they have found their ace card: their products save lives. Brad Sorenson, senior vice president, Global Supply Chain, shares how the company's' relationship with suppliers has helped Boston Scientific secure supply as typical lead times for components quintupled from three to 15 months.

Jodi Eddy, chief information and digital officer at Boston Scientific, explains the link between broadband access and telehealth access—and the subsequent impact on healthcare disparities.

Boston Scientific’s tumor-targeting glass microbeads continue to shatter expectations for cancer treatment. The latest results of a long-term study showed adding TheraSpheres to a standard chemotherapy regimen could extend survival for patients with colorectal cancer that has spread to the liver.

CAUTION: In the U.S., the use of TheraSphere for mCRC is for investigational use only as the safety and effectiveness have not been established.

As the University of Minnesota launches the Center for Medical Device Cybersecurity, KSTP reports how Boston Scientific is one of five Minnesota device companies that have provided funding.

Boston Scientific Chief Digital Health Officer David Feygin shares his career journey and leadership tips with professionals on the Ivy Podcast.

Boston Scientific recently announced FDA clearance of the EXALT Model B single-use bronchoscope, intended for bedside procedures in intensive care units or in the operating room. Medgadget had the opportunity to speak with Dave Pierce, Executive Vice President and President, MedSurg and President, Endoscopy, at Boston Scientific, about the new bronchoscope.

BostonScientific MedSurg EVP Dave Pierce shares his excitement for the future of our Endoscopy and Urology/Pelvic Health businesses, and why he’s proud of how the company has navigated through the uncertainty of the past year.

Boston Scientific has won FDA 510(k) clearance for a single-use bronchoscope designed to eliminate the infection risk associated with reusable devices.

Opinion: Boston Scientific's president of endoscopy writes that government policies have enabled the medtech giant to reinvest profits in multiple areas of innovation. "Patients cannot benefit from bets we don’t make.

A new study using Boston Scientific's EkoSonic endovascular system (EKOS) aims to address current gaps in clinical guidelines for the treatment of pulmonary embolism.

The advent of cardiac resynchronization therapy (CRT) changed the landscape of heart failure management options, but perhaps a third of patients receiving biventricular pacemakers for CRT don't respond to it. The observational study, SMART MSP, demonstrated that CRT with multisite LV pacing (MSP) made responders out of half of patients in whom CRT had failed over the previous 6 months in a prospective trial.

CMS granted a NTAP for single-use duodenoscopes, which applies to Boston Scientific's Exalt Model D single-use duodenoscope, as part of the FY 2022 hospital IPPS. This means that beginning Oct. 1, 2021, CMS will give hospitals additional device reimbursement when single-use duodenoscopes are used for eligible cases in the hospital inpatient setting.

David Knapp, Vice President of Research and Development for Peripheral Interventions at Boston Scientific, joins us to talk about the value of innovation culture, how businesses today go about creating and sustaining an innovative company and embracing the sustainability imperative.

Fueled by billions of its own dollars, the medical technology industry's successes are built on a willingness to invest with a long-term horizon. Some of our bets may never pay off, but our successes have the potential to transform millions of lives.

Boston Scientific has exerted its right to acquire the remaining shares of Farapulse, a company that has developed a pulsed field ablation system for the treatment of cardiac arrhythmias.

Vance Brown has worked in the company's legal department for 20 years. But he's facing new challenges as the GC, including the task of bringing a global workforce back to the office.